

Torben Bjerregaard Larsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6456250/publications.pdf>

Version: 2024-02-01

149
papers

6,541
citations

71061

41
h-index

66879

78
g-index

150
all docs

150
docs citations

150
times ranked

7601
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral anti-coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study. <i>British Journal of Haematology</i> , 2022, 197, 223-231.	1.2	6
2	Clinical risk factors for retinal artery occlusions: a nationwide case-control study. <i>International Ophthalmology</i> , 2022, 42, 2483-2491.	0.6	7
3	Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3847-3855.	1.1	4
4	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study. <i>Stroke</i> , 2022, 53, 2559-2568.	1.0	5
5	Assigning diagnosis codes using medication history. <i>Artificial Intelligence in Medicine</i> , 2022, 128, 102307.	3.8	6
6	Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting. <i>Pharmacoeconomics - Open</i> , 2022, 6, 483-494.	0.9	1
7	Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-11.	1.1	3
8	Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f101-f110.	1.4	14
9	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. <i>American Journal of Medicine</i> , 2021, 134, 67-75.e5.	0.6	0
10	Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark. <i>Circulation</i> , 2021, 143, 907-920.	1.6	12
11	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 31-39.	1.4	5
12	Venous Thromboembolism and Major Bleeding in Patients With Coronavirus Disease 2019 (COVID-19): A Nationwide, Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2283-2293.	2.9	44
13	Management of Cancer-Associated Venous Thrombosis: A Nationwide Survey among Danish Oncologists. <i>TH Open</i> , 2021, 05, e188-e194.	0.7	2
14	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. <i>Cancer Medicine</i> , 2021, 10, 4405-4414.	1.3	8
15	Characteristics of patients receiving extended treatment after incident venous thromboembolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 332-342.	1.2	2
16	Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2021, 134, 868-876.e5.	0.6	15
17	First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. <i>American Journal of Medicine</i> , 2021, , .	0.6	4
18	Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). <i>American Journal of Cardiology</i> , 2020, 125, 48-54.	0.7	20

#	ARTICLE	IF	CITATIONS
19	Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2020, 133, 463-472.e5.	0.6	5
20	Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 30-38.	1.2	3
21	Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 791-800.	0.6	6
22	Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 805-814.	1.8	13
23	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. <i>Thrombosis Research</i> , 2020, 191, 1-8.	0.8	9
24	Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. <i>American Journal of Medicine</i> , 2020, 133, e269-e279.	0.6	17
25	Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 201-208.	0.6	3
26	Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1672-1682.	1.3	1
27	Towards Assigning Diagnosis Codes Using Medication History. <i>Lecture Notes in Computer Science</i> , 2020, , 203-213.	1.0	2
28	Sex differences in risk of incident venous thromboembolism in heart failure patients. <i>Clinical Research in Cardiology</i> , 2019, 108, 101-109.	1.5	15
29	Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating “valvular heart disease”™ in a nationwide cohort study. <i>Europace</i> , 2019, 21, 33-40.	0.7	27
30	Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007030.	2.1	39
31	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2019, 50, 939-946.	1.0	34
32	Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study. <i>Cancer Medicine</i> , 2019, 8, 1044-1053.	1.3	14
33	Psychotropic drug use following venous thromboembolism versus diabetes mellitus in adolescence or young adulthood: a Danish nationwide cohort study. <i>BMJ Open</i> , 2019, 9, e026159.	0.8	2
34	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. <i>Cerebrovascular Diseases</i> , 2019, 48, 236-243.	0.8	6
35	Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 787-794.e4.	0.6	17
36	Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study. <i>ESC Heart Failure</i> , 2018, 5, 319-326.	1.4	11

#	ARTICLE	IF	CITATIONS
37	The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. <i>American Journal of Medicine</i> , 2018, 131, 574.e13-574.e27.	0.6	46
38	Patients'™ knowledge and attitudes regarding living with implantable electronic devices: results of a multicentre, multinational patient survey conducted by the European Heart Rhythm Association. <i>Europace</i> , 2018, 20, 386-391.	0.7	35
39	Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2018, 118, S45-S60.	1.8	12
40	Response by Overvad et al to Letter Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA ₂ DS ₂ -VASc Score Rather Than CHA ₂ DS ₂ -VASc?" <i>Circulation</i> , 2018, 138, 443-444.	1.6	0
41	Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2018, 131, 1067-1074.e4.	0.6	55
42	Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 857-873.	0.6	27
43	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation. <i>Scientific Reports</i> , 2018, 8, 15805.	1.6	14
44	Disease progression after ablation for atrial flutter compared with atrial fibrillation: A nationwide cohort study. <i>International Journal of Clinical Practice</i> , 2018, 72, e13258.	0.8	11
45	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017, 19, euw242.	0.7	67
46	Death and thrombo-embolic risk after ablation of atrial flutter compared with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2017, 19, euw107.	0.7	13
47	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. <i>JAMA Internal Medicine</i> , 2017, 177, 563.	2.6	75
48	Premature atrial complexes in an ischemic stroke population and risk of recurrent stroke: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 447-455.	0.6	3
49	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor. <i>JAMA Cardiology</i> , 2017, 2, 872.	3.0	44
50	Using a personalized decision support algorithm for dosing in warfarin treatment: A randomised controlled trial. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2017, 25, 1-6.	1.0	5
51	Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2017, 19, 1737-1742.	0.7	34
52	Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey. <i>Europace</i> , 2017, 19, 1896-1902.	0.7	53
53	All Types of Hemorrhagic Stroke Are Not Created Equally"Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 1399.	2.6	0
54	Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. <i>BMJ Open</i> , 2017, 7, e018209.	0.8	23

#	ARTICLE	IF	CITATIONS
55	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	0.8	83
56	Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity-Weighted Cohort Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	4
57	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2017, 356, j510.	2.4	275
58	The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. <i>PLoS ONE</i> , 2017, 12, e0188482.	1.1	48
59	Effectiveness of self-managed oral anticoagulant therapy in patients with recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 524-529.	1.8	9
60	Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1236-1244.	0.9	60
61	Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1494-1499.	0.7	11
62	Misconceptions on Interpretation of Risk Prediction Tools in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, e31.	0.6	4
63	Stroke and mortality after atrial fibrillation—a global struggle. <i>Lancet, The</i> , 2016, 388, 1131-1132.	6.3	0
64	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. <i>Scientific Reports</i> , 2016, 6, 27410.	1.6	67
65	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ, The</i> , 2016, 353, i3189.	3.0	351
66	Letter by Nielsen et al Regarding Article, “Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score of 1: Systematic Review and Meta-Analysis” <i>Stroke</i> , 2016, 47, e193.	1.0	0
67	Response. <i>Chest</i> , 2016, 149, 1590-1591.	0.4	0
68	β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002597.	1.6	49
69	Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 979-985.	1.0	11
70	Recalibration of the HAS-BLED Score. <i>Chest</i> , 2016, 149, 311-314.	0.4	9
71	Risk of venous thromboembolism in patients with heart failure. <i>Lancet Haematology, the</i> , 2016, 3, e6-e7.	2.2	0
72	Anticoagulant therapy after venous thromboembolism and 10-year mortality. <i>International Journal of Cardiology</i> , 2016, 208, 72-78.	0.8	16

#	ARTICLE	IF	CITATIONS
73	Diabetes mellitus and risk of ischemic stroke in patients with heart failure and no atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 209, 1-6.	0.8	15
74	Self-managed oral anticoagulant therapy: a call for implementation. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 255-257.	0.6	9
75	A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 203, 785-790.	0.8	1
76	Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0152269.	1.1	6
77	Management of paediatric arrhythmias in Europe: authors' reply. <i>Europace</i> , 2015, 17, 1879.2-1880.	0.7	0
78	Comparison of Atrial Fibrillation Guidelines. <i>Journal of General Internal Medicine</i> , 2015, 30, 1404-1404.	1.3	0
79	Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 819-824.	0.7	14
80	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. <i>Circulation</i> , 2015, 132, 517-525.	1.6	225
81	Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2015, 17, 314-317.	0.7	30
82	Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. <i>Clinical Research in Cardiology</i> , 2015, 104, 1088-1096.	1.5	36
83	Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 1596-1600.	0.7	46
84	EHRA research network surveys: 6 years of EP wires activity. <i>Europace</i> , 2015, 17, 1733-1738.	0.7	0
85	Recurrent Stroke. <i>Stroke</i> , 2015, 46, 2491-2497.	1.0	36
86	Atrial flutter and thromboembolic risk: a systematic review. <i>Heart</i> , 2015, 101, 1446-1455.	1.2	54
87	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2168-2174.	1.0	72
88	Rivaroxaban as anticoagulant therapy in short bowel syndrome. Report of three cases. <i>Thrombosis Research</i> , 2015, 135, 568-570.	0.8	11
89	Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort study. <i>Thrombosis Research</i> , 2015, 135, 643-647.	0.8	15
90	Female sex is associated with a lower risk of stroke in patients with heart failure. <i>American Heart Journal</i> , 2015, 169, 396-403.e2.	1.2	5

#	ARTICLE	IF	CITATIONS
91	Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. <i>Chest</i> , 2015, 147, 1651-1658.	0.4	43
92	Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA ₂ DS ₂ -VASc Score. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1385-1394.	1.2	141
93	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , 2015, 104, 418-429.	1.5	87
94	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1155-1163.	0.6	1
95	Assessment of the CHA ₂ DS ₂ -VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1030.	3.8	262
96	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
97	Atrial Fibrillation Patients Categorized as "Not for Anticoagulation" According to the 2014 Canadian Cardiovascular Society Algorithm Are Not "Low Risk". <i>Canadian Journal of Cardiology</i> , 2015, 31, 24-28.	0.8	17
98	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients. <i>Europace</i> , 2015, 17, 169-170.	0.7	0
99	Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>PLoS ONE</i> , 2014, 9, e114445.	1.1	54
100	Postoperative Atrial Fibrillation Prophylaxis After Lung Surgery: Systematic Review and Meta-Analysis. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1989-1997.	0.7	51
101	Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up. <i>PLoS ONE</i> , 2014, 9, e113627.	1.1	22
102	Mortality Rate in Type 2 Myocardial Infarction: Observations from an Unselected Hospital Cohort. <i>American Journal of Medicine</i> , 2014, 127, 295-302.	0.6	140
103	Improvement of anticoagulant treatment using a dynamic decision support algorithm. <i>Thrombosis Research</i> , 2014, 133, 375-379.	0.8	9
104	Warfarin or novel oral anticoagulants for atrial fibrillation?. <i>Lancet, The</i> , 2014, 383, 931-933.	6.3	23
105	Myocardial Ischemic Events in "Real World" Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin. <i>American Journal of Medicine</i> , 2014, 127, 329-336.e4.	0.6	63
106	Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 650-656.e5.	0.6	100
107	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e21.	0.6	0
108	Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2014, 127, 1172-1178.e5.	0.6	43

#	ARTICLE	IF	CITATIONS
109	Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2014, 16, 698-702.	0.7	7
110	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 981-988.	1.8	99
111	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. <i>Chest</i> , 2014, 146, 1337-1346.	0.4	34
112	Monitoring of anticoagulant therapy applying a dynamic statistical model. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 110, 380-388.	2.6	4
113	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 61, 596.	1.2	2
114	Body Mass Index and Adverse Events in Patients with Incident Atrial Fibrillation. <i>American Journal of Medicine</i> , 2013, 126, 640.e9-640.e17.	0.6	91
115	Efficacy and Safety of Dabigatran Etxilate and Warfarin in "Real-World" Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2264-2273.	1.2	387
116	Alcohol intake and prognosis of atrial fibrillation. <i>Heart</i> , 2013, 99, 1093-1099.	1.2	51
117	Added Predictive Ability of the CHA ₂ -DS ₂ -VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 335-342.	0.9	41
118	Letter by Christensen et al Regarding Article, "New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation". <i>Circulation</i> , 2012, 126, e45; author reply e46.	1.6	3
119	Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2027-2031.	1.9	40
120	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. <i>BMJ, The</i> , 2012, 345, e7097-e7097.	3.0	110
121	Indirect comparison studies "are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2012, 108, 405-406.	1.8	21
122	Prevention of Venous Thromboembolism with New Oral Anticoagulants versus Standard Pharmacological Treatment in Acute Medically Ill Patients. <i>Drugs</i> , 2012, 72, 1755-1764.	4.9	15
123	Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 738-746.	1.2	272
124	Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 251-260.	1.9	82
125	Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1301-1307.	1.9	39
126	Self-testing and self-management of oral anticoagulation therapy in children. <i>Thrombosis and Haemostasis</i> , 2011, 106, 391-397.	1.8	24

#	ARTICLE	IF	CITATIONS
127	Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. <i>Critical Care</i> , 2010, 14, R41.	2.5	64
128	Severe arterial thrombosis in a family with type III protein S deficiency caused by a frameshift mutation in the PROS1 gene. <i>Thrombosis Research</i> , 2010, 126, e159-e161.	0.8	0
129	International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy. <i>Thrombosis and Haemostasis</i> , 2009, 101, 563-569.	1.8	41
130	The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. <i>Thrombosis Research</i> , 2009, 124, 208-212.	0.8	3
131	Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 358-365.	0.5	18
132	Haemostatis activity in rectal cancer patients exposed to preoperative radiotherapy: a clinical prospective cohort study. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 276-282.	0.5	2
133	Preoperative Plasma D-Dimer Is a Predictor of Postoperative Deep Venous Thrombosis in Colorectal Cancer Patients. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 446-451.	0.7	54
134	Denaturing High-performance Liquid Chromatography mutation analysis in patients with reduced Protein S levels. <i>Clinica Chimica Acta</i> , 2008, 390, 76-81.	0.5	3
135	More Studies on Outcomes Using Biochemical Diagnostic Tests Are Needed: Findings from the Danish Society of Clinical Biochemistry. <i>Clinical Chemistry</i> , 2008, 54, 1254-1256.	1.5	3
136	Combined use of clinical pre-test probability and D-dimer test in the diagnosis of preoperative deep venous thrombosis in colorectal cancer patients. <i>Thrombosis and Haemostasis</i> , 2008, 99, 396-400.	1.8	10
137	Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: A population-based nested case-control study. <i>Thrombosis Research</i> , 2007, 120, 505-509.	0.8	214
138	ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 300-304.	1.9	61
139	A review of medical records and discharge summary data found moderate to high predictive values of discharge diagnoses of venous thromboembolism during pregnancy and postpartum. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 316-319.	2.4	41
140	Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. <i>Epidemiology</i> , 2003, 14, 328-32.	1.2	41
141	Platelets and Anticoagulant Capacity in Patients with Inflammatory Bowel Disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 92-96.	0.5	46
142	Hyperhomocysteinaemia, Coagulation Pathway Activation and Thrombophilia in Patients with Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 62-67.	0.6	44
143	Validity of D-dimer tests in the diagnosis of deep vein thrombosis: a prospective comparative study of three quantitative assays. <i>Journal of Internal Medicine</i> , 2002, 252, 36-40.	2.7	32
144	D-dimer test in deep vein thrombosis - reply. <i>Journal of Internal Medicine</i> , 2002, 252, 576-576.	2.7	0

#	ARTICLE	IF	CITATIONS
145	Sudden Infant Death Syndrome, Childhood Thrombosis, and Presence of Genetic Risk Factors for Thrombosis. <i>Thrombosis Research</i> , 2000, 98, 233-239.	0.8	6
146	Evaluation of a Simple Dosage Scheme for Transition from Phenprocoumon to Warfarin in Oral Anticoagulation. <i>Thrombosis Research</i> , 2000, 98, 157-163.	0.8	11
147	The Arg506Gln Mutation (FV Leiden) Among a Cohort of 4188 Unselected Danish Newborns. <i>Thrombosis Research</i> , 1998, 89, 211-215.	0.8	41
148	Effect of Anticoagulant Therapy on the Hypercoagulable State in Patients Carrying the Factor V Arg506Gln Mutation. <i>Thrombosis Research</i> , 1998, 92, 157-162.	0.8	6
149	Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 0, , .	1.8	0